U.S. markets open in 1 hour 34 minutes
  • S&P Futures

    3,816.25
    -29.75 (-0.77%)
     
  • Dow Futures

    30,819.00
    -263.00 (-0.85%)
     
  • Nasdaq Futures

    13,307.75
    -87.75 (-0.66%)
     
  • Russell 2000 Futures

    2,114.70
    -23.80 (-1.11%)
     
  • Crude Oil

    51.75
    -1.38 (-2.60%)
     
  • Gold

    1,842.70
    -23.20 (-1.24%)
     
  • Silver

    25.22
    -0.63 (-2.45%)
     
  • EUR/USD

    1.2167
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.1090
    0.0000 (0.00%)
     
  • Vix

    23.55
    +1.97 (+9.13%)
     
  • GBP/USD

    1.3665
    -0.0065 (-0.48%)
     
  • USD/JPY

    103.7640
    +0.2590 (+0.25%)
     
  • BTC-USD

    31,531.58
    +1,047.84 (+3.44%)
     
  • CMC Crypto 200

    627.07
    +17.08 (+2.80%)
     
  • FTSE 100

    6,657.70
    -57.72 (-0.86%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

Supernus drug meets main goal of study in adults with ADHD

Dec 22 (Reuters) - Supernus Pharmaceuticals Inc said on Tuesday its experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study test in adults.

The drug, SPN-812, is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in children 6 to 17 years of age. (Reporting by Manojna Maddipatla in Bengaluru Editing by Chris Reese)